Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.20.2
Commitments and Contingencies (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Aug. 31, 2019
Sep. 30, 2018
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Jan. 31, 2018
Commitments and Contingencies (Textual)                
Commitments and contingencies, description         In connection with becoming a public company, the Company obtained director and officer liability insurance at a premium cost of approximately $1,810,000, with approximately $104,000 of such insurance premiums expensed during the six months ended June 30, 2020, all of which is accrued as of June 30, 2020. The remaining balance of approximately $1,706,000 was included under other current asset and insurance payable on the Company's condensed consolidated balance sheet at June 30, 2020.      
Operating Lease [Member]                
Commitments and Contingencies (Textual)                
Lease term, description The Company entered into a leasing agreement for office space in New Jersey. Monthly rent is $2,106, plus electrical utilities and the lease expires on July 31, 2020.       The Company leased office space in Dallas, Texas under month-to-month lease arrangements.   The Company leased office space in Dallas, Texas under month-to-month lease arrangements.  
LP-184 [Member]                
Commitments and Contingencies (Textual)                
Annual fees     $ 0   $ 30,000      
LP-100 [Member]                
Commitments and Contingencies (Textual)                
Annual fees         $ 30,000      
AF Chemicals [Member]                
Commitments and Contingencies (Textual)                
Commitments and contingencies, description         The ability for the Company to pay AF Chemicals additional amounts ranging from $25,000 to $50,000 for each one, two, and three year extension to such development time requirements, with additional extensions beyond three years to be negotiated by the Company and AF Chemicals. During the three and six months ended June 30, 2020, the Company paid AF Chemicals $25,000 and $50,000, respectively, relating to the IND filing milestone extension fee for LP-184, $12,500 and $25,000 of which were expensed during the three and six months ended June 30, 2020, respectively, and included under research and development expenses in the accompanying condensed consolidated statements of operations. The Company paid AF Chemicals $37,500 during the year ended December 31, 2019 in connection with extension of the IND filing milestone for LP-184, none of which was paid during the three and six months ended June 30, 2019. Amounts of $9,375 and $18,750 were expensed during the three and six months ended June 30, 2019, respectively, related to this extension payment, and included under research and development expenses in the accompanying condensed consolidated statements of operations.      
AF Chemicals [Member] | LP-184 [Member]                
Commitments and Contingencies (Textual)                
Annual fees     0 $ 0 $ 30,000 $ 30,000    
Expenses     7,500 7,500 15,000 15,000    
AF Chemicals [Member] | LP-100 [Member]                
Commitments and Contingencies (Textual)                
Annual fees     0 0 30,000 30,000    
Expenses     7,500 $ 7,500 15,000 $ 15,000    
EU Grant [Member]                
Commitments and Contingencies (Textual)                
Research and development   50.00%            
Research and development expenses not exceeding GBP   $ 24,215            
Patents [Member]                
Commitments and Contingencies (Textual)                
Upfront payments     25,000   $ 25,000      
Net revenue, percentage         50.00%      
BioNumerik Pharmaceuticals [Member]                
Commitments and Contingencies (Textual)                
Upfront payments               $ 25,000
Commitments and contingencies, description         In the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100 million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative revenue in excess of $1 billion.      
Amounts payable     $ 11,000   $ 11,000   $ 11,000